Loading…
Loading…
A state-level competitiveness incentive stack (up to $50m PA Edge tax credits + $25m PA SITES grant + $25m Pennsylvania First grant + up to $5m RACP workforce funding = $100m public money) used to win a company-specific manufacturing-siting decision from Eli Lilly, aimed at onshoring production of GLP-1 weight-loss medicines currently facing severe US supply constraints. The public/private leverage ratio is roughly 1:35 (public $100m vs. private $3.5bn), a much larger absolute public package than Pennsylvania's prior Eos Energy battery deal ($22m) but structurally the same DCED playbook (PA First + PA SITES/RACP + tax credits) — hence a low severity score despite the large headline private-investment figure, since the state's own outlay is modest relative to it.
relevant to reducing reliance on offshore (largely EU/Ireland) incretin-drug production capacity amid persistent US shortages.
reshoring US capacity in the run-up to/alongside the parallel MFN-drug-pricing and tariff-exemption agreements the administration has struck with several peer pharma companies (AbbVie, Bristol Myers Squibb, Novartis, Genentech, Boehringer Ingelheim, Gilead, Sanofi, Amgen, Merck) — those deals condition tariff relief on US manufacturing/pricing commitments, though Lilly is not one of the named MFN counterparties in this register as of filing.
continuing the DCED state-incentive-stack pattern (PA First + PA SITES/RACP) also seen in the Eos Energy Pittsburgh deal.
DOD Defense Production Act Title III, or IRA-adjacent manufacturing tax credits) layered on top of this state package — not disclosed in the DCED release.
public package tied to the 850-job commitment.